Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-01-08

FDA Approved: TRIAMTERENE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Chartwell RX, LLC)

View source ↗

Summary

FDA approves a supplemental application for Triamterene and Hydrochlorothiazide submitted by Chartwell RX, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Triamterene and Hydrochlorothiazide (Triamterene and hydrochlorothiazide)

Snippet

SUPPL AP for TRIAMTERENE AND HYDROCHLOROTHIAZIDE (TRIAMTERENE AND HYDROCHLOROTHIAZIDE)